If I could only buy one ASX 200 share today, it would be CSL Ltd (ASX: CSL).
Let me explain why.
Image source: Getty Images
I think headwinds are easing
The ASX 200 biotech company has faced huge headwinds over the past 18 months.
From uninspiring financial results, to a revenue and growth profit guidance downgrade, a surprise restructure announcement, and even a shock CEO exit, several events have spooked investors and sent the company's share price south.
At the time of writing, the CSL share price is up 0.8% to $141.93 a piece. Today's uptick represents a 5.5% rebound from an eight-year low of $134.64 just two weeks ago.
There is a long way to go until CSL shares recover the 43% losses shed over the past 12 months, but the latest uptick is a great sign that the share price has finally bottomed out and is starting to rebound.
There is huge demand for its products
Another reason I'd buy CSL shares today is because of huge global demand for its productions.
CSL develops and delivers biotherapies and vaccines but at the core of its business are its plasma-derived medicines. These include immunoglobulins, albumin, and clotting factors.
At the time of writing, the company's blood plasma division dominates the global market for rare blood disorders and immunoglobulin products.
Demand for these plasma therapies is rocketing right now. There is recurring demand, limited competition and low supply which means CSL is well placed to absorb a significant portion of the market.
For context, reports recently stated that the blood plasma derivatives market was valued at $52.16 billion in 2025. By 2033 it is expected to explode to $104.30 billion.
The ASX 200 company is growing
Despite the latest headwinds, CSL has still managed to maintain business growth. The company has even experienced periods of double‑digit profit growth, and its forecasts underpin a recovery over the long term.
Sequoia Wealth Management's Peter Day, who has a buy recommendation on CSL shares, recently pointed out that the company has posted a significant increase in revenue during the past three years and delivered earnings growth that is compounding at double-digit rates.
There's a great potential upside ahead
I'm confident that we'll see great things out of the CSL share price this year.
Analysts are bullish too.
TradingView data shows that 12 out of 18 analysts have a buy or strong buy rating on the ASX 200 stock. They tip an upside of up to 95% to $275.56 over the next 12 months, at the time of writing.
It's seems like CSL shares are a no-brainer to me.
